Monod Bio builds modular de novo protein-based biosensors that emit bioluminescent signals when they recognize target molecules. Its LucCage platform combines computational protein design, protein engineering, and machine learning to create one-step sensors that unite binding, transduction, and amplification. Monod has produced sensors targeting the SARS-CoV-2 spike protein, cancer receptors, and cardiac troponin, with work published in Nature and Nature Biotechnology. The company announced a $25M seed financing to advance LucCage, build prototypes for diagnostics, and expand its capabilities. Monod plans to double the size of its research and engineering teams over the next 18 months to scale development and ensure diagnostic reliability. The platform is positioned for applications across biotechnology and medicine, emphasizing rapid, sensitive, and low-cost analytical assays.

Total raised

$25M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2022